SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)


Study Number
499719
Phase
II
Age Group
Adult
Purpose

Primary Objectives: o Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. o Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: - To assess the safety and tolerability of SAR408701 in combination with ramucirumab - To assess the durability of the response to treatment with SAR408701 in combination with ramucirumab - To assess efficacy of SAR408701 in combination with ramucirumab on progression free survival - To assess the pharmacokinetic (PK) profile of SAR408701 and ramucirumab when given in combination - To assess the immunogenicity of SAR408701 when given in combination with ramucirumab

Full Title

Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, nonsquamous, non small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors,…

ClinicalTrials.Gov ID
NCT04394624

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.